Press release from Business Wire
LifeSci Advisors Initiates Coverage on Keryx Biopharmaceuticals
<p class=' bwtextaligncenter'> <b>Report Cites Potential of Keryx' Phase III Programs in Cancer and Renal Disease</b> </p> <p class=' bwtextaligncenter'> <b>Report is Available for Download at </b><a href='http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lifesciadvisors.com&esheet=6381679&lan=en-US&anchor=www.lifesciadvisors.com&index=1&md5=1373709c2afcf92a6a8e0c8e511623a5'><b>www.lifesciadvisors.com</b></a> </p>
Monday, August 02, 2010
LifeSci Advisors Initiates Coverage on Keryx Biopharmaceuticals12:44 EDT Monday, August 02, 2010 NEW YORK (Business Wire) -- LifeSci Advisors, LLC., a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage on Keryx Biopharmaceuticals (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. “Keryx has multiple robust late-stage programs underway and our analysis indicates that perifosine, the company's lead candidate, has blockbuster potential as an anti-cancer agent,” commented Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “Additionally, we believe Zerenex, the company's therapeutic in development for the treatment of patients with end-stage renal disease, may have significant safety, efficacy and dosing advantages over currently marketed therapies in its class. Given these attributes, we believe that positive results from the ongoing Phase III trial of Zerenex could position the drug to capture significant market share.” LifeSci Advisors' 56-page Initiation Report contains a detailed discussion of Keryx Biopharmaceuticals pipeline products, including perifosine for relapsed/refractory multiple myeloma and advanced colorectal cancer and Zerenex for hyperphosphatemia associated with end-stage renal disease. The report outlines competitive positioning and growth opportunities for these products, which are now in Phase III clinical trials under Special Protocol Assessment (SPA) with the FDA. The report highlights recent clinical achievements, short-term and long-term expected milestones, relevant market dynamics, and risks. Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on Keryx Biopharmaceuticals as developments occur. The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics. About Keryx Biopharmaceuticals: Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing perifosine, a novel, potentially first-in-class, oral anti-cancer agent that inhibits key signal transduction pathways, which are associated with programmed cell death, cell growth, cell differentiation and cell survival. Perifosine is currently in Phase III clinical development for both refractory advanced colorectal cancer and multiple myeloma. Each of the Phase III programs is being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase III clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Please visit www.keryx.com for more information. About LifeSci Advisors: LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com. Important Disclosures: The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer. Forward-looking statements: This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.